Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

New Mexico HPV Pap Registry Steering Committee

Research output: Contribution to journalArticle

Abstract

There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.

Original languageEnglish (US)
Pages (from-to)177-179
Number of pages3
JournalPreventive Medicine
Volume111
DOIs
StatePublished - Jun 1 2018

Fingerprint

Uterine Cervical Neoplasms
Cell Biology
Quality-Adjusted Life Years
Early Detection of Cancer
Population
Costs and Cost Analysis

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. / New Mexico HPV Pap Registry Steering Committee.

In: Preventive Medicine, Vol. 111, 01.06.2018, p. 177-179.

Research output: Contribution to journalArticle

New Mexico HPV Pap Registry Steering Committee. / Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. In: Preventive Medicine. 2018 ; Vol. 111. pp. 177-179.
@article{30fcad586f6842f58027361a1033ad38,
title = "Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.",
abstract = "There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.",
author = "{New Mexico HPV Pap Registry Steering Committee} and Castle, {Philip E.} and Wheeler, {Cosette M.} and Campos, {Nicole G.} and Stephen Sy and Burger, {Emily A.} and Kim, {Jane J.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.ypmed.2018.03.011",
language = "English (US)",
volume = "111",
pages = "177--179",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

AU - New Mexico HPV Pap Registry Steering Committee

AU - Castle, Philip E.

AU - Wheeler, Cosette M.

AU - Campos, Nicole G.

AU - Sy, Stephen

AU - Burger, Emily A.

AU - Kim, Jane J.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.

AB - There is limited information on the cost-inefficiencies of non-adherence to recommended cervical cancer screening or the potential value for improving non-adherence. We estimated the incremental value of adhering to recommended screening every three years with cytology, using a disease simulation model that integrated real-world screening practice data from New Mexico. The amount that can be spent to improve adherence was estimated by calculating the incremental net monetary benefit (INMB) under scenarios of Current Practice (assuming a population of mixed adherence) and Uniformly Non-Adherent populations with imperfect or perfect adherence to follow-up of screen-positive women. Getting unscreened women screened every three years by cytology was a better value than increasing screening in the under-screened or reducing screening in the over-screened. For example, INMBs were $3998 for screening previously unscreened women versus $136 for eliminating annual screening at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year gained. Strategies to reach unscreened women are potentially high-value investments.

UR - http://www.scopus.com/inward/record.url?scp=85043764957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043764957&partnerID=8YFLogxK

U2 - 10.1016/j.ypmed.2018.03.011

DO - 10.1016/j.ypmed.2018.03.011

M3 - Article

VL - 111

SP - 177

EP - 179

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

ER -